Dyslipidaemia and cardiorenal disease: mechanisms, therapeutic opportunities and clinical trials
Authors:
- Ashley B. IrishAIAshley B. Irish
- Gursharan K. DograGDGursharan K. Dogra
- Gerald F. WattsGWGerald F. Watts
- 1 February 2008
- journal article
- review article
- Published by Elsevier in Atherosclerosis
- Vol. 196 (2) , 823-834
Abstract
No abstract availableKeywords
This publication has 102 references indexed in Scilit:
- Mechanisms for the Hypotriglyceridemic Effect of Marine Omega-3 Fatty AcidsThe American Journal of Cardiology, 2006
- Dietary Omega-3 Fatty Acid Intake and Cardiovascular RiskThe American Journal of Cardiology, 2006
- Statin Safety and Drug Interactions: Clinical ImplicationsThe American Journal of Cardiology, 2006
- Increased targeting of cardiovascular risk factors in patients with chronic kidney disease does not improve atheroma burden or cardiovascular functionAmerican Heart Journal, 2006
- Endocrinology and Dialysis Jean L. HolleySeries Editor: Lipid Abnormalities Associated with End‐Stage Renal DiseaseSeminars in Dialysis, 2006
- EzetimibeClinical Pharmacokinetics, 2005
- Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and HospitalizationNew England Journal of Medicine, 2004
- Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronic renal insufficiencyKidney International, 2004
- The risk of cardiovascular disease in adults who have had childhood nephrotic syndromePediatric Nephrology, 2004
- Arterial Calcifications, Arterial Stiffness, and Cardiovascular Risk in End-Stage Renal DiseaseHypertension, 2001